This revealed a wide spectrum of p53 mutations in 64.7% of patients and KRAS mutations in 35.3% of patients (G12C, G13C, G12D, and Q61H) in ASS1‐deficient non‐squamous NSCLC. Here, TP53 is linked to non-small cell lung carcinoma.